Impact of %6 HES 130/0.4 and %4 Gelofusine Infusion on Kidney Function in the Living-donor Liver Transplantation

Completed

• Conditions: Patients Undergoing Liver Transplantation
• Interventions: Drug: %6 HES and %4 Gelofusine

• Registration Number: NCT02079350
• Lead Sponsor: Turkiye Yuksek Ihtisas Education and Research Hospital

Brief Summary

Although the negative impacts of colloid solutions with high molecular weight on renal functions, combination of lower molecular weight colloid varieties with crystalloid solutions and its use during intraoperative period have been subject to current research. Since the first liver transplantation, pre-or post-transplantation renal problems are still among the main causes of mortality and morbidity. The aim of the study was to evaluate the effects of fluid replacement solutions used intraoperatively on renal functions in elective living-donor liver transplantation.This study was approved by the Ethics Committee of Hospital and all patients were informed and gave written consent. Participants were patients scheduled for elective living-donor liver transplantation. Patients with normal renal function were randomly allocated to infusion with 6% HES 130/0.4 (HES Group) and 4% Gelofusine (GEL Group). Blood samples were obtained before induction of anesthesia (baseline), at the end of the operation, and postoperative days 1 and 4. Different eGFR formulas using creatinine (MDRD, CKD-EPI, and Cockraud Gault) were used to calculate estimated glomerular filtration rates.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-01
• Primary Completion: 2013-11
• Study Completion: 2013-12
• Status Verified: 2014-03
• Study First Submitted: 2014-03-01
• Study First Submitted QC: 2014-03-01
• Last Update Submitted: 2014-03-01
• Study First Posted: 2014-03-05
• Last Update Posted: 2014-03-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

-Normal kidney function

Exclusion Criteria

• anormal kidney function
• cadaveric transplantation
• emergency operation
• patients less than 18 years old

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
%4 Gelofusine	%6 HES and %4 Gelofusine	patients administered %4 Gelofusine during liver transplantation
%6 HES	%6 HES and %4 Gelofusine	patients administered %6 HES during liver transplantation

Primary Outcome Measures

Name	Time	Method
renal dysfunction	1 month

Secondary Outcome Measures

Name	Time	Method
mortality	1 month

Trial Locations

Locations (1)

Turkey Yuksek Ihtisas Education and Research Hospital, Anesthesiology Clinic; 🇹🇷 Ankara, Turkey